Parexel Taps Rob Goodwin as COO

Parexel, a global clinical research organization (CRO), has appointed Rob Goodwin as Chief Operating Officer (COO).

In his new role, Goodwin will report to CEO Peyton Howell and be responsible for leading the core clinical functions, specifically, project management, clinical and data operations, inclusive of early phase clinical units, real world research, and the operational excellence office.

“Rob’s deep industry experience and knowledge, biopharma relationships and proven, hands-on expertise are all enormous advantages to Parexel and our team as we continue to advance what it means to be a successful clinical research organization,” said Peyton Howell. “The addition of Rob as Chief Operating Officer further supports our strategic focus as we work to meet – and exceed – our customers’ needs and accelerate our own growth objectives. He is the ideal person for this role and the entire team is excited to collaborate with him as we move forward.”

Experience

Goodwin brings nearly 30 years of biopharmaceutical clinical development experience, most recently serving as Senior Vice President, Clinical Development and Operations, at Pfizer. In this role, he was responsible for establishing, maintaining, and overseeing the global clinical development and operational capabilities required to develop Phase I through Phase IV study protocols and plans, execute clinical trials and deliver post marketing studies to support the introduction of new therapies for patients.

Prior to Pfizer, Goodwin helped develop the Electronic Data Capture program at Bayer. He holds a Bachelor’s Degree from Eastern Connecticut State University, a Master’s Degree from Southern Connecticut State University and an MBA from Fairleigh Dickinson University.

“I’m honored and excited to join Parexel,” said Goodwin. “I look forward to working alongside our talented team to drive strong execution, deliver the highest quality and reliability, foster meaningful innovation, and provide exceptional service for our customers – all with a continued focus on what matters most, delivering life-saving treatments to patients.”